However, HDAC inhibitors have been shown to have anticancer activity through downregulation of CHK1, Wee1, BRCA1, and/or Rad51.282,317–326 There are currently several FDA-approved HDAC inhibitors, though none for the treatment of AML. Here, CHEK1 is linked to acute myeloid leukemia.